Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Abraham

Showing results (801-810 of 826) with videos related to

Pageof 83
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2019
Fibroblast growth factor receptor influences primary cilium length through an interaction with intestinal cell kinaseMichaela Kunova Bosakova, Alexandru Nita, Tomas Gregor, et al.
Journal of the American College of Cardiology|October 30, 2024
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCMAhmad Masri, Lubna Choudhury, Roberto Barriales-Villa, et al.
Journal of the American College of Cardiology|September 1, 2024
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic CardiomyopathySheila M Hegde, Brian L Claggett, Xiaowen Wang, et al.
Journal of the American College of Cardiology|April 10, 2024
Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic CardiomyopathyMartin S Maron, Masliza Mahmod, Azlan Helmy Abd Samat, et al.
Pharmaceutics|April 26, 2025
The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience ProgramStephen B Hanauer, Esther A Torres, Patricia Aragon-Han, et al.
Journal of Neurosurgery. Spine|October 4, 2024
Outcome prediction following lumbar disc surgery: a longitudinal study of outcome trajectories, prognostic factors, and risk modelsJeffrey J Hébert, Erin E Bigney, Sarah Nowell, et al.
JAMA Cardiology|September 4, 2024
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical TrialMatthew M Y Lee, Ahmad Masri, Michael E Nassif, et al.
European Heart Journal|September 1, 2024
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trialCaroline J Coats, Ahmad Masri, Roberto Barriales-Villa, et al.
Diabetes Research and Clinical Practice|January 5, 2024
Incidence, prevalence, and mortality of type 1 diabetes in children and youth in Burkina Faso 2013-2022Yempabou Sagna, W P Abraham H Bagbila, Nongoba Sawadogo, et al.
JACC. Heart Failure|June 20, 2025
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCMSara Saberi, Theodore P Abraham, Lubna Choudhury, et al.
Pageof 83

Showing results (801-810 of 826) with videos related to

Sort By:
Pageof 83
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2019
Fibroblast growth factor receptor influences primary cilium length through an interaction with intestinal cell kinaseMichaela Kunova Bosakova, Alexandru Nita, Tomas Gregor, et al.
Journal of the American College of Cardiology|October 30, 2024
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCMAhmad Masri, Lubna Choudhury, Roberto Barriales-Villa, et al.
Journal of the American College of Cardiology|September 1, 2024
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic CardiomyopathySheila M Hegde, Brian L Claggett, Xiaowen Wang, et al.
Journal of the American College of Cardiology|April 10, 2024
Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic CardiomyopathyMartin S Maron, Masliza Mahmod, Azlan Helmy Abd Samat, et al.
Pharmaceutics|April 26, 2025
The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience ProgramStephen B Hanauer, Esther A Torres, Patricia Aragon-Han, et al.
Journal of Neurosurgery. Spine|October 4, 2024
Outcome prediction following lumbar disc surgery: a longitudinal study of outcome trajectories, prognostic factors, and risk modelsJeffrey J Hébert, Erin E Bigney, Sarah Nowell, et al.
JAMA Cardiology|September 4, 2024
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical TrialMatthew M Y Lee, Ahmad Masri, Michael E Nassif, et al.
European Heart Journal|September 1, 2024
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trialCaroline J Coats, Ahmad Masri, Roberto Barriales-Villa, et al.
Diabetes Research and Clinical Practice|January 5, 2024
Incidence, prevalence, and mortality of type 1 diabetes in children and youth in Burkina Faso 2013-2022Yempabou Sagna, W P Abraham H Bagbila, Nongoba Sawadogo, et al.
JACC. Heart Failure|June 20, 2025
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCMSara Saberi, Theodore P Abraham, Lubna Choudhury, et al.
Pageof 83